Skip to content
Screener

Biohaven BHVN Pre-Tax Income

Pre-Tax Income at other companies

Eli Lilly logo
Eli LillyLLY
$9.25B+36.4%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$111.32M-30.5%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$80.26M+172%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-$43.19M-289%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$36.34M-75.1%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
-$150.7M-42.3%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.17B+41.2%
Enterprise value$2.18B+31.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Biohaven’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001935979-26-000045
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Total operating expenses130,428221,561
Loss from operations(130,428)(221,561)
Other income, net168493
Loss before provision for income taxes(130,260)(221,068)
Provision for income taxes272609
Net loss$(130,532)$(221,677)
Net loss per share — basic and diluted$(0.88)$(2.17)
Weighted average common shares outstanding—basic and diluted147,615,197101,943,396

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Biohaven's pre-tax income?
Biohaven (BHVN) reported pre-tax income of -$130.26M in Q1 2026.
How has Biohaven's pre-tax income changed year-over-year?
Biohaven's pre-tax income increased by 41.1% year-over-year, from -$221.07M to -$130.26M.
What is the long-term trend for Biohaven's pre-tax income?
Over 3 years (2022 to 2025), Biohaven's pre-tax income has grown at a 9.0% compound annual growth rate (CAGR), from -$569.84M to -$737.38M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Biohaven's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude